Compositions and methods for WT1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
1. An isolated polypeptide comprising the amino acid sequence provided in SEQ ID NO:455.
2. A composition comprising the polypeptide of claim 1 .
3. The composition of claim 2 wherein the composition comprises a physiologically acceptable carrier or excipient.
4. The composition according to claim 2 wherein the composition comprises an immunostimulant.
5. The composition according to claim 4 wherein the immunostimulant preferentially enhances a T cell response in a patient.
6. The composition according to claim 4 wherein the immunostimulant comprises monophosphoryl lipid A (MPL).